Search results
Hikma is a leading provider of high-quality medicines across North America, MENA and Europe. Learn more about its strategy, performance, responsibility and career opportunities.
- Products
We provide patients across our markets with 760+...
- Careers
The majority of our efforts in this area are channeled...
- About
Hikma enters the Spanish generic injectables market,...
- Overview
Our highly experienced pharmaceutical team develops,...
- Newsroom
Hikma expands its agreement with AFT Pharmaceuticals for the...
- Us Locations
Hikma Pharmaceuticals USA Inc. 200 Connell Drive, 4th Floor...
- Who is Hikma
We have 29 manufacturing plants, eight R&D centres and...
- Suppliers
Our Supplier Code of Conduct sets out our values and...
- Our Culture
Listen to Nika Beck, Manufacturing Specialist - Hikma 503B,...
- Products
Website. www .hikma .com. Hikma Pharmaceuticals plc is a British multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products. It was founded by Samih Darwazah in Amman, Jordan in 1978.
Hikma is a global pharmaceutical company that produces and distributes generic, specialty and branded medicines. Follow its LinkedIn page to learn about its products, services, news, events and career opportunities.
Jun 15, 2023 · Hikma Pharmaceuticals, a global company with a local presence in the US, has expanded its portfolio of sterile injectable medicines to over 150 products. Dobutamine Injection, USP is indicated for inotropic support in adults with cardiac decompensation.
People also ask
What does Hikma do?
Did Hikma Pharmaceuticals buy Boehringer Ingelheim?
What is Hikma branded business segment?
What is Hikma 503B?
Sep 27, 2021 · Hikma, a global pharmaceutical company, announces the acquisition of Custopharm, a US-based sterile injectables company with a differentiated product portfolio and R&D pipeline. The deal adds 13 approved products and additional pipeline products to Hikma's US injectables business and enhances its R&D capabilities.